Press Releases

Year

August 12, 2020

Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results

BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to Producing Base Editing Therapeutics Broad Partnering Strategy Continues to Advance and Expand the

July 30, 2020

Beam Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following August investor conferences: William Blair Biotech Focus

June 15, 2020

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam

May 26, 2020

Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference

May 12, 2020

Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results

Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo Novel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with Corresponding HbS

April 28, 2020

Beam Therapeutics to Present Updated Data Highlighting Base Editing Programs for Sickle Cell Disease at 23rd ASGCT Annual Meeting

Data Further Validate Two Novel Base Editing Approaches Leveraging Naturally Occurring Biology to Correct Sickle Cell Mutation CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base

April 28, 2020

Beam Therapeutics to Present First Data Highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at 23rd ASGCT Annual Meeting

Preclinical Data Demonstrate Efficient Base Editing Leading to Durable Levels of Precise Gene Correction In Vivo CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today

March 30, 2020

Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results

Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs CAMBRIDGE, Mass. , March 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing,

March 16, 2020

Beam Therapeutics Announces Key R&D Appointments

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key leadership appointments, including the promotion of Manmohan Singh, Ph.D., from vice president to

February 11, 2020

Beam Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2020-- Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Center

Investors & Media

Stockholder Tools

Press Releases

Press Releases

Investors & Media

Stockholder Tools